| Autor: |
Izumiyama K; North Japan Hematology Study Group (NJHSG); Blood Disorders Center, Aiiku Hospital, Sapporo. izumi5318@yahoo.co.jp., Inao T; Department of Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo., Goto H; North Japan Hematology Study Group (NJHSG); Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo., Harada S; North Japan Hematology Study Group (NJHSG); Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo., Senjo H; North Japan Hematology Study Group (NJHSG); Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo., Suto K; North Japan Hematology Study Group (NJHSG); Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo., Hashiguchi J; North Japan Hematology Study Group (NJHSG); Department of Hematology, Kitami Red Cross Hospital, Kitami., Ogasawara R; North Japan Hematology Study Group (NJHSG); Department of Hematology, Sapporo Hokuyu Hospital, Sapporo., Saga T; North Japan Hematology Study Group (NJHSG); Department of Hematology, Kin-ikyo Chuo Hospital, Sapporo., Igarashi T; North Japan Hematology Study Group (NJHSG); Department of Hematology, Tenshi Hospital, Sapporo., Wakasa K; North Japan Hematology Study Group (NJHSG); Division of Hematology, Hokkaido P.W.F.A.C. Obihiro-Kosei General Hospital, Obihiro., Kasahara I; North Japan Hematology Study Group (NJHSG); Department of Hematology, Sapporo City General Hospital, Sapporo., Takeda Y; North Japan Hematology Study Group (NJHSG); Department of Hematology, Tonan Hospital, Sapporo., Yamaguchi K; North Japan Hematology Study Group (NJHSG); Department of Hematology, Teine Keijinkai Hospital, Sapporo., Shigematsu A; North Japan Hematology Study Group (NJHSG); Department of Hematology, Kushiro Rosai Hospital, Kushiro., Takahata M; North Japan Hematology Study Group (NJHSG); Department of Hematology, Sapporo-Kosei General Hospital, Sapporo., Fujimoto K; North Japan Hematology Study Group (NJHSG); Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo., Haseyama Y; North Japan Hematology Study Group (NJHSG); Department of Hematology, Tonan Hospital, Sapporo., Nagashima T; North Japan Hematology Study Group (NJHSG); Department of Hematology, Kitami Red Cross Hospital, Kitami., Sakai H; North Japan Hematology Study Group (NJHSG); Department of Hematology, Teine Keijinkai Hospital, Sapporo., Kakinoki Y; North Japan Hematology Study Group (NJHSG); Department of Hematology, Asahikawa City Hospital, Asahikawa., Kurosawa M; North Japan Hematology Study Group (NJHSG); Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo., Yokota I; Department of Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo., Teshima T; North Japan Hematology Study Group (NJHSG); Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo. |
| Abstrakt: |
Information regarding follow-up duration after treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) is important. However, a clear endpoint has yet to be established. We enrolled a total of 2,182 patients newly diagnosed with DLBCL between 2008 and 2018. The median age of the patients was 71 years. All patients were treated with rituximab- and anthracycline-based chemotherapies. Each overall survival (OS) was compared with the age- and sex-matched Japanese general population (GP) data. At a median follow-up of 3.4 years, 985 patients experienced an event and 657 patients died. Patients who achieved an event-free survival (EFS) at 36 months (EFS36) had an OS equivalent to that of the matched GP (standard mortality ratio [SMR], 1.17; P=0.1324), whereas those who achieved an EFS24 did not have an OS comparable to that of the matched GP (SMR, 1.26; P=0.0095). Subgroup analysis revealed that relatively old patients (>60 years), male patients, those with limited-stage disease, those with a good performance status, and those with low levels of soluble interleukin 2 receptor already had a comparable life expectancy to the matched GP at an EFS24. In contrast, relatively young patients had a shorter life expectancy than matched GP, even with an EFS36. In conclusion, an EFS36 was shown to be a more suitable endpoint for newly diagnosed DLBCL patients than an EFS24. Of note, younger patients require a longer EFS period than older patients in order to obtain an equivalent life expectancy to the matched GP. |
